Form 4: KALA BIO CFO Mary Reumuth Sells Shares to Cover Tax Obligations

Mary Reumuth, CFO of KALA BIO, Inc., sold 4,163 shares of common stock on June 26, 2024, to cover tax withholding obligations related to vested restricted stock units.

Summary

• On June 26, 2024, Mary Reumuth, the Chief Financial Officer of KALA BIO, Inc., sold 4,163 shares of the company's common stock.
• The sale was executed at a weighted average price of $4.75 per share, with individual transactions ranging from $4.50 to $5.09.
• This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on November 9, 2020.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs) granted on June 22, 2023.
• Following the reported transaction, Reumuth still beneficially owns 60,187 shares, which includes 44,131 unvested RSUs.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (stock sale for tax obligations) and doesn't inherently indicate positive or negative sentiment regarding the company's performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Sales under 10b5-1 plans are common and allow insiders to sell shares at predetermined times to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Insider sales are a common occurrence in publicly traded companies.
• The use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations.
• Comparable companies often see similar filings from their executives related to stock options and RSU vesting.

Stakeholder Impact

• The sale of shares by a high-ranking officer could be perceived negatively by some shareholders, although the explanation provided mitigates this concern.
• The impact on other stakeholders is likely minimal, as this is a personal financial transaction of an executive.

Key Dates